Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 19,751	$ 21,304
Prepaid expenses and other current assets	821	1,118
Total current assets	20,572	22,422
Long-term assets
Property and equipment, net	23	33
Operating lease right-of-use assets	206	421
Intangible assets, net	11,178	12,637
Other long-term assets		40
Total assets	31,979	35,553
Current liabilities
Accounts payable	2,324	3,254
Accrued compensation	1,282	728
Accrued clinical trial site costs	2,826	3,420
Operating lease liabilities	239	282
Other current liabilities	671	323
Total current liabilities	7,342	8,007
Long-term liabilities
Contingent liability for Essentialis purchase price	9,437	9,547
Long-term lease liabilities		175
Total liabilities	16,779	17,760
Commitments and contingencies (Note 6)
Stockholders’ equity
Common stock, $0.001 par value, 100,000,000 shares authorized, 8,159,382 and 5,324,287 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively.	8	80
Additional paid-in-capital	247,130	231,068
Accumulated deficit	(231,936)	(213,355)
Accumulated other comprehensive loss	(2)
Total stockholders’ equity	15,200	17,793
Total liabilities and stockholders’ equity	$ 31,979	35,553
2018 PIPE Warrant Liability [Member]
Long-term liabilities
Warrant liability		$ 31